Intravenous Management of Acute Hypotension in Obstructive Hypertrophic Cardiomyopathy

Pathophysiology

• Reducing afterload or increasing myocardial contractility worsens left ventricular outflow tract (LVOT) obstruction and can precipitate cardiovascular collapse in obstructive HCM. Class III (Harm) recommendation. 1

Contraindicated Intravenous Agents

• Positive inotropic agents (e.g., dopamine, dobutamine, norepinephrine) are harmful because they increase contractility and exacerbate LVOT obstruction. Class III (Harm). 1
• Pure vasodilators such as intravenous nicardipine or clevidipine lower systemic vascular resistance, reduce afterload, and aggravate obstruction. Class III (Harm). 2
• Intravenous verapamil is potentially dangerous in the setting of systemic hypotension or severe dyspnea, as its vasodilatory effect can trigger life‑threatening hemodynamic collapse. Class III (Harm). 1

First‑Line Therapy: Volume Resuscitation

• Administer intravenous crystalloid fluids to optimize preload; increased preload improves cardiac output and diminishes LVOT gradients. Class I, Level B. 1

Second‑Line Therapy: Pure Vasoconstrictors

• If hypotension persists after adequate fluid loading, initiate intravenous phenylephrine—a pure α‑adrenergic vasoconstrictor without inotropic activity. Class I, Level B recommendation. 1
• Phenylephrine raises systemic vascular resistance, thereby improving arterial pressure while simultaneously reducing LVOT obstruction because it does not increase contractility. Class I, Level B. 4

Adjunctive Therapy

• Intravenous β‑blockers may be added to phenylephrine to further blunt contractility, lower heart rate, and prolong diastolic filling time, addressing both afterload and contractile components. Class IIa, Level B (implicit from source). 5

Mechanistic Rationale for Vasoconstrictor Benefit

• Increasing afterload with pure vasoconstrictors diminishes the Venturi effect across the LVOT, lowers the pressure gradient that drives systolic anterior motion of the mitral valve, and preserves coronary perfusion pressure. Class I, Level B. 1

Monitoring During Phenylephrine Infusion

• Continuously monitor arterial blood pressure and heart rate to titrate phenylephrine safely. Class I, Level B. 5
• Watch for signs of excessive vasoconstriction (e.g., cool extremities, reduced urine output) and adjust therapy accordingly. Class I, Level B. 5
• Assess resolution of hypotension‑related symptoms and reduction of LVOT obstruction (e.g., decreased murmur intensity). Class I, Level B. 1

Transition to Long‑Term Management

• After acute stabilization, switch to oral negative inotropic agents—β‑blockers or non‑dihydropyridine calcium channel blockers—for chronic control of obstructive HCM. Class I, Level B. 1